Press release
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova
DelveInsight's "Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Type 2 Diabetes, historical and forecasted epidemiology as well as the Type 2 Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Type 2 Diabetes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Type 2 Diabetes Market Forecast [https://www.delveinsight.com/sample-request/type-2-diabetes-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Type 2 Diabetes Market Report:
*
The Type 2 Diabetes market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In April 2025, Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company specializing in the development of novel peptide-based therapies, has announced the enrollment of the first participant in its Phase 2b ZUPREME-2 trial. This study targets individuals with overweight or obesity and type 2 diabetes, evaluating the efficacy and safety of once-weekly subcutaneous doses of petrelintide, a long-acting amylin analogue, in comparison to a placebo.
*
In February 2025, Tandem Diabetes Care has received FDA clearance for its Control-IQ+ automated insulin delivery system, now approved for use in individuals with type 2 diabetes.
*
In February 2025, Sotagliflozin, which has FDA approval for treating type 2 diabetes and kidney disease, has demonstrated a substantial reduction in the risk of heart attack and stroke among high-risk patients, presenting a promising option for cardiovascular protection.
*
In January 2025, The FDA has approved a new indication for semaglutide to help lower the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, as announced by Novo Nordisk.
*
As per the Centers for Disease Control and Prevention (CDC), over 34 million individuals in the United States, roughly 1 in 10, are affected by diabetes. The majority, around 90-95%, have type 2 diabetes. While type 2 diabetes commonly arises in individuals aged 45 and older, there is a growing trend of its occurrence among children, teenagers, and young adults.
*
As per the Centers for Disease Control and Prevention, over 34 million people in the United States-roughly 1 in 10-are living with diabetes, with around 90-95% of these cases being type 2 diabetes. While it typically occurs in adults over the age of 45, an increasing number of children, teenagers, and young adults are also being diagnosed with the condition.
*
According to Diabetes UK, type 2 diabetes is the most common form of the disease, making up approximately 90% of all diabetes cases in the United Kingdom.
*
Over 34 million individuals in the United States-around 1 in 10-are living with diabetes, with type 2 diabetes accounting for roughly 90-95% of these cases. While it typically emerges in adults over the age of 45, an increasing number of children, teenagers, and young adults are also being diagnosed (Centers for Disease Control and Prevention, n.d.).
*
Key Type 2 Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others
*
Key Type 2 Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others
*
The Type 2 Diabetes market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Type 2 Diabetes pipeline products will significantly revolutionize the Type 2 Diabetes market dynamics.
Type 2 Diabetes Overview
Type 2 diabetes is a chronic metabolic disorder characterized by elevated levels of blood glucose (sugar). It is the most common form of diabetes and typically develops in adulthood, though it can occur in children as well. In type 2 diabetes, the body either resists the effects of insulin (a hormone that helps regulate blood sugar) or doesn't produce enough insulin to maintain normal blood glucose levels.
Get a Free sample for the Type 2 Diabetes Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/type-2-diabetes-market [https://www.delveinsight.com/report-store/type-2-diabetes-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Type 2 Diabetes Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Type 2 Diabetes Epidemiology Segmentation:
The Type 2 Diabetes market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Type 2 Diabetes
*
Prevalent Cases of Type 2 Diabetes by severity
*
Gender-specific Prevalence of Type 2 Diabetes
*
Diagnosed Cases of Episodic and Chronic Type 2 Diabetes
Download the report to understand which factors are driving Type 2 Diabetes epidemiology trends @ Type 2 Diabetes Epidemiology Forecast [https://www.delveinsight.com/sample-request/type-2-diabetes-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Type 2 Diabetes Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Type 2 Diabetes market or expected to get launched during the study period. The analysis covers Type 2 Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Type 2 Diabetes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Type 2 Diabetes Therapies and Key Companies
*
Tirzepatide/LY3298176: Eli Lilly and Company
*
Danuglipron: Pfizer
*
RGT001-075: Regor Pharmaceuticals Inc.
*
AZD0186: AstraZeneca
*
ECC5004: Eccogene
*
PF-07081532: Pfizer
*
XW014: Sciwind Biosciences USA Co., Ltd.
*
MN-001: MediciNova
*
SPI-62: Sparrow Pharmaceuticals
*
HTD1801: HighTide Biopharma Pty Ltd
*
Semaglutide: Novo Nordisk A/S
*
BMF-219: Biomea Fusion Inc.
*
ALT-801: Altimmune, Inc.
*
MBL949: Novartis
*
LY3457263: Eli Lilly and Company
*
AMG 133: Amgen
*
DD01: Neuraly, Inc.
*
CT-868: Carmot Therapeutics, Inc.
*
IVA337: Inventiva Pharma
*
INV-202: Inversago Pharma Inc
*
AT-001: Applied Therapeutics, Inc.
Discover more about therapies set to grab major Type 2 Diabetes market share @ Type 2 Diabetes Treatment Landscape [https://www.delveinsight.com/sample-request/type-2-diabetes-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Type 2 Diabetes Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Type 2 Diabetes Companies: Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc., Altimmune, Inc., Novartis, Amgen, Neuraly, Inc., Carmot Therapeutics, Inc., Inventiva Pharma, Inversago Pharma Inc, Applied Therapeutics, Inc., and others
*
Key Type 2 Diabetes Therapies: Tirzepatide/LY3298176, Danuglipron, RGT001-075, AZD0186, ECC5004, PF-07081532, XW014, MN-001, SPI-62, HTD1801, Semaglutide, BMF-219, ALT-801, MBL949, LY3457263, AMG 133, DD01, CT-868, IVA337, INV-202, AT-001, and others
*
Type 2 Diabetes Therapeutic Assessment: Type 2 Diabetes current marketed and Type 2 Diabetes emerging therapies
*
Type 2 Diabetes Market Dynamics: Type 2 Diabetes market drivers and Type 2 Diabetes market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Type 2 Diabetes Unmet Needs, KOL's views, Analyst's views, Type 2 Diabetes Market Access and Reimbursement
To know more about Type 2 Diabetes companies working in the treatment market, visit @ Type 2 Diabetes Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/type-2-diabetes-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Type 2 Diabetes Market Report Introduction
2. Executive Summary for Type 2 Diabetes
3. SWOT analysis of Type 2 Diabetes
4. Type 2 Diabetes Patient Share (%) Overview at a Glance
5. Type 2 Diabetes Market Overview at a Glance
6. Type 2 Diabetes Disease Background and Overview
7. Type 2 Diabetes Epidemiology and Patient Population
8. Country-Specific Patient Population of Type 2 Diabetes
9. Type 2 Diabetes Current Treatment and Medical Practices
10. Type 2 Diabetes Unmet Needs
11. Type 2 Diabetes Emerging Therapies
12. Type 2 Diabetes Market Outlook
13. Country-Wise Type 2 Diabetes Market Analysis (2020-2034)
14. Type 2 Diabetes Market Access and Reimbursement of Therapies
15. Type 2 Diabetes Market Drivers
16. Type 2 Diabetes Market Barriers
17. Type 2 Diabetes Appendix
18. Type 2 Diabetes Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=type-2-diabetes-market-to-expand-significantly-by-2034-states-delveinsight-report-eli-lilly-and-company-regor-pharma-astrazeneca-eccogene-pfizer-sciwind-biosciences-usa-co-ltd-medicinova]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova here
News-ID: 4033919 • Views: …
More Releases from ABNewswire
Star8 Corporation (STRH) Revolutionizing Energy Efficiency and Electric Mobility
The Tomahawk DualTech System, developed by Star8's subsidiary TOMAHAWK SRL, is a patent-pending technology that optimizes motor and mechatronic performance, slashing energy consumption and heat waste while boosting operational efficiency. Designed for high-energy-demand industries, DualTech's innovative business model offers zero-cost installation for clients, with Star8 earning 10% of the energy cost savings.
In the rapidly evolving landscape of sustainable technology, Star8 Corporation (OTC: STRH) is emerging as a transformative force, strategically…
Trusted by North Admiral Homeowners for Exceptional Chimney Flashing - The Mad H …
Designed to create a watertight seal between the chimney and the roof, it prevents rainwater from seeping into the interior structure. In the North Admiral area, homeowners have increasingly turned to The Mad Hatter Chimney Sweep, LLC for professional craftsmanship and reliable flashing installation, ensuring their homes remain safe and structurally sound through all seasons.
Expert Craftsmanship in Chimney Care
Among the essential components of a well-maintained roofing system, Chimney Flashing [https://themadhatterchimneysweep.com/#:~:text=The%20Mad%20Hatter-,Chimney%20Sweep,-Seattle%20today%3A%20(206]…
Victoria B. Thompson Inspires Readers with the Release of "Passing the Baton" - …
Image: https://www.abnewswire.com/upload/2025/10/c58612c1f4766164179f77a1a0c024fc.jpg
Air Force veteran, HR supervisor, and purpose-driven entrepreneur Victoria B. Thompson has officially released her new book, Passing the Baton, a compelling exploration of how individuals can transform resilience into legacy and purpose into impact. More than a memoir, Passing the Baton serves as a beacon for readers seeking to align their achievements with a greater calling: to live intentionally and lead meaningfully.
"Passing the Baton is more than a…
Cape Cod's Blue Ocean Life Expands Local Roots into a Mission-Driven Lifestyle B …
Blue Ocean Life Company LLC, founded and based on Cape Cod, Massachusetts, announces its growth from local markets and pop-ups into a mission-driven lifestyle brand blending coastal culture with mental wellness advocacy. Founded by Mike Coughlin after his own journey of overcoming adversity through ocean healing, the brand remains deeply tied to its New England roots while expanding into a national movement that resonates strongly with Gen Z and Millennial…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
